Hormonal
GLP-1 receptor agonists (GLP-1 RAs) promote weight loss and improve glycemic control through multiple mechanisms including increased satiety, slowed gastric emptying, and enhanced insulin secretion, with semaglutide 2.4 mg showing the highest efficacy.
GLP-1 receptor agonists like semaglutide are highly effective for weight loss and blood sugar control. Semaglutide 2.4 mg taken once weekly (either orally or by injection) resulted in an average loss of 15.3 kg over 68 weeks in clinical trials. This is significantly more effective than placebo. These drugs work by increasing satiety, slowing digestion, and improving insulin function. They are suitable for adults with obesity or type 2 diabetes.
GLP-1 receptor agonists (GLP-1 RAs) are a new class of antihyperglycemic drugs that enhance appropriate pancreatic β-cell secretion, pancreatic α-cell (glucagon) suppression, decrease liver glucose production, increase satiety through their action on the central nervous system, slow gastric emptying time, and increase insulin action on peripheral tissue. ... semaglutide in higher doses promotes weight loss and can be used as a drug to treat obesity.
Why this rating
Based on multiple large clinical trials (LEADER, SUSTAIN-6, STEP 1) and meta-analyses cited.
Source
Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors
Jasna Klen et al. · International Journal of Molecular Sciences · 2022
DOI 10.3390/ijms23073451
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →